Статии с изисквания за обществен достъп - GIULIA SIRAVEGNAНаучете повече
Не е налице никъде: 4
Integrating liquid biopsies into the management of cancer
G Siravegna, S Marsoni, S Siena, A Bardelli
Nature reviews Clinical oncology 14 (9), 531-548, 2017
Изисквания: Government of Italy
Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies
G Mauri, EG Pizzutilo, A Amatu, K Bencardino, L Palmeri, EF Bonazzina, ...
Cancer treatment reviews 73, 41-53, 2019
Изисквания: European Commission
Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know
M Calandri, G Siravegna, SM Yevich, G Stranieri, C Gazzera, S Kopetz, ...
European Radiology 30, 4496-4503, 2020
Изисквания: US National Institutes of Health, AIRC Foundation for Cancer Research in Italy
Blood-based prediction of tumor relapse: the cfDNA forecast
G Siravegna, RB Corcoran
Cancer Discovery 8 (10), 1213-1215, 2018
Изисквания: US National Institutes of Health
Налице някъде: 54
Detection of circulating tumor DNA in early-and late-stage human malignancies
C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ...
Science translational medicine 6 (224), 224ra24-224ra24, 2014
Изисквания: US National Institutes of Health, Wellcome Trust, Government of Italy
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ...
Nature 486 (7404), 532-536, 2012
Изисквания: US National Institutes of Health
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ...
Nature medicine 21 (7), 795-801, 2015
Изисквания: US National Institutes of Health, Government of Spain, Government of Italy
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
AN Hata, MJ Niederst, HL Archibald, M Gomez-Caraballo, FM Siddiqui, ...
Nature medicine 22 (3), 262-269, 2016
Изисквания: US National Institutes of Health
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ...
Cancer discovery 3 (6), 658-673, 2013
Изисквания: US National Institutes of Health
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
G Germano, S Lamba, G Rospo, L Barault, A Magrì, F Maione, M Russo, ...
Nature 552 (7683), 116-120, 2017
Изисквания: Swiss National Science Foundation, Government of Italy
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
L Goyal, SK Saha, LY Liu, G Siravegna, I Leshchiner, LG Ahronian, ...
Cancer discovery 7 (3), 252-263, 2017
Изисквания: US National Institutes of Health, Government of Italy, V Foundation, USA …
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
AR Parikh, I Leshchiner, L Elagina, L Goyal, C Levovitz, G Siravegna, ...
Nature medicine 25 (9), 1415-1421, 2019
Изисквания: US National Institutes of Health, Cancer Research UK, European Commission …
Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer
M Russo, G Siravegna, LS Blaszkowsky, G Corti, G Crisafulli, ...
Cancer discovery 6 (2), 147-153, 2016
Изисквания: US National Institutes of Health, Government of Italy, Damon Runyon Cancer …
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK …
N Tanaka, JJ Lin, C Li, MB Ryan, J Zhang, LA Kiedrowski, AG Michel, ...
Cancer discovery 11 (8), 1913-1922, 2021
Изисквания: US National Institutes of Health
How liquid biopsies can change clinical practice in oncology
G Siravegna, B Mussolin, T Venesio, S Marsoni, J Seoane, C Dive, ...
Annals of Oncology 30 (10), 1580-1590, 2019
Изисквания: Cancer Research UK, European Commission, Government of Spain, Government of …
TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma
L Goyal, L Shi, LY Liu, F Fece de la Cruz, JK Lennerz, S Raghavan, ...
Cancer discovery 9 (8), 1064-1079, 2019
Изисквания: US Department of Defense, US National Institutes of Health, V Foundation, USA
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer
M Russo, S Misale, G Wei, G Siravegna, G Crisafulli, L Lazzari, G Corti, ...
Cancer discovery 6 (1), 36-44, 2016
Изисквания: Government of Italy
Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer
AR Parikh, EE Van Seventer, G Siravegna, AV Hartwig, A Jaimovich, Y He, ...
Clinical Cancer Research 27 (20), 5586-5594, 2021
Изисквания: US National Institutes of Health
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer
S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ...
Science translational medicine 6 (224), 224ra26-224ra26, 2014
Изисквания: Government of Italy
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
S Arena, B Bellosillo, G Siravegna, A Martínez, I Canadas, L Lazzari, ...
Clinical cancer research 21 (9), 2157-2166, 2015
Изисквания: Government of Spain, Government of Italy
Информацията за публикацията и осигуреното финансиране се определя автоматично от компютърна програма